ACAD
41.2
+1.01
+2.51%
AEMD
8.68
-0.06
-0.69%
APRI
1.67
+0.03
+1.83%
ARNA
3.925
-0.06
-1.506%
ATEC
1.35
-0.01
-0.74%
CNAT
5.45
-0.01
-0.18%
CRXM
0.502
+0.012
+2.4694%
CYTX
0.661
-0.071
-9.6735%
DXCM
71.72
+0.45
+0.63%
GNMK
9.17
-0.2
-2.13%
HALO
17.35
-0.33
-1.87%
ILMN
206.08
-2.54
-1.22%
INNV
0.152
0.00
-0.0656%
INO
8.41
-0.17
-1.98%
ISCO
0.05
0.00
0.00%
ISIS
67.32
+0.61
+0.91%
LGND
88.11
-0.04
-0.05%
LPTN
0.285
-0.006
-2.0962%
MBVX
2.32
+0.06
+2.65%
MEIP
1.9
+0.01
+0.53%
MNOV
3.95
0.00
0.00%
MRTX
36.66
+0.48
+1.33%
MSTX
0.54
0.00
0.00%
NBIX
43.86
+1.1
+2.57%
NUVA
50.55
+0.93
+1.87%
ONCS
7.95
+0.35
+4.61%
ONVO
5.01
+0.05
+1.01%
OREX
4.9
-0.02
-0.41%
OTIC
24.52
+0.19
+0.78%
QDEL
21.67
-0.57
-2.56%
RCPT
164.89
+0.06
+0.04%
RGLS
14.12
+0.54
+3.98%
RMD
58.82
+0.17
+0.29%
SCIE
0.021
+0.004
+20.000%
SPHS
1.07
-0.04
-3.60%
SRNE
13.79
-0.01
-0.07%
TROV
10.96
-0.04
-0.36%
VICL
0.95
-0.005
-0.5131%
VOLC
17.99
0.00
0.00%
ZGNX
1.7
+0.21
+14.09%
ACAD
41.2
+1.01
+2.51%
AEMD
8.68
-0.06
-0.69%
APRI
1.67
+0.03
+1.83%
ARNA
3.925
-0.06
-1.506%
ATEC
1.35
-0.01
-0.74%
CNAT
5.45
-0.01
-0.18%
CRXM
0.502
+0.012
+2.4694%
CYTX
0.661
-0.071
-9.6735%
DXCM
71.72
+0.45
+0.63%
GNMK
9.17
-0.2
-2.13%
HALO
17.35
-0.33
-1.87%
ILMN
206.08
-2.54
-1.22%
INNV
0.152
0.00
-0.0656%
INO
8.41
-0.17
-1.98%
ISCO
0.05
0.00
0.00%
ISIS
67.32
+0.61
+0.91%
LGND
88.11
-0.04
-0.05%
LPTN
0.285
-0.006
-2.0962%
MBVX
2.32
+0.06
+2.65%
MEIP
1.9
+0.01
+0.53%
MNOV
3.95
0.00
0.00%
MRTX
36.66
+0.48
+1.33%
MSTX
0.54
0.00
0.00%
NBIX
43.86
+1.1
+2.57%
NUVA
50.55
+0.93
+1.87%
ONCS
7.95
+0.35
+4.61%
ONVO
5.01
+0.05
+1.01%
OREX
4.9
-0.02
-0.41%
OTIC
24.52
+0.19
+0.78%
QDEL
21.67
-0.57
-2.56%
RCPT
164.89
+0.06
+0.04%
RGLS
14.12
+0.54
+3.98%
RMD
58.82
+0.17
+0.29%
SCIE
0.021
+0.004
+20.000%
SPHS
1.07
-0.04
-3.60%
SRNE
13.79
-0.01
-0.07%
TROV
10.96
-0.04
-0.36%
VICL
0.95
-0.005
-0.5131%
VOLC
17.99
0.00
0.00%
ZGNX
1.7
+0.21
+14.09%
Home » Bio: Kevin Lustig

Bio: Kevin Lustig

Recently named one of five national finalists for “Entrepreneur of the Year” by Entrepreneur magazine, Kevin is a cell biologist with 30 years of research experience in academia and pharma. He is founder and CEO of Assay Depot, a software company that is transforming how medical research is done.  In 2013, he founded Bio, Tech and Beyond, a non-profit community laboratory dedicated to life science innovation.  In 2001, Kevin founded Kalypsys, a biopharmaceutical company that raised over $170 million in venture funding and put five drug candidates into clinical trials. Prior to Kalypsys, he directed lead discovery at Tularik, a biopharmaceutical company purchased by Amgen for $2.5 billion. He carried out postdoctoral work in Cell Biology at Harvard Medical School after receiving a PhD degree from the University of California, San Francisco. Kevin has a M.S. degree from the University of Missouri, Columbia and an A.B. degree, magna cum laude, from Cornell University.  His research discoveries have been published in Science, Nature and other leading scientific journals and he has eight technology patents.